LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.89 -1.56

Buy Sell

Overview

Share price change

24h

Current

Min

1.8199999999999998

Max

2.07

Key metrics
By Trading Economics
Income	1.2M -31M
Sales	-70K 1.3M
EPS	-0.26
Profit margin	-2,402.848
Employees	161
EBITDA	12M -30M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+151.58% upside

Dividends
By Dow Jones
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	-31M 223M
Previous open	3.45
Previous close	1.89

News Sentiment

By Acuity

50%

153 / 344 Ranking in Healthcare

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 cze 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 cze 2026, 23:45 UTC

Acquisitions, Mergers, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 cze 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 cze 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 cze 2026, 23:43 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 cze 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 cze 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 cze 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 cze 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 cze 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 cze 2026, 20:51 UTC

Earnings

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 cze 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 cze 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 cze 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 cze 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 cze 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 cze 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 cze 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 cze 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 cze 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 cze 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 cze 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 cze 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 cze 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 cze 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 cze 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 cze 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 cze 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

151.58% upside

12 Months Forecast

Average 4.78 USD 151.58%

High 7 USD

Low 2.2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

153 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.